🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application
ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company …
By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner What does it mean to be an effective therapist? Surely, most new graduates are entering the therapy profession with energy, enthusiasm, and …
Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness? Read More »
Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, …
Copyright © 2023 ATMA
